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Confirmatory randomized-controlled trials require solid justifications especially with regard to 
whether the experimental intervention is promising. Such evidence is generated in exploratory 
trials. However, empirical evidence shows that the quality of such trials is still suboptimal. More 
generally, the development process of health-care interventions and especially of drugs, remains 
inefficient. Over the last 10 to 20 years a vast amount of methodological work has been published 
about exploratory trials. This overview introduces some of the concepts and recent developments 
in the field. 
Methods 
A narrative approach was taken for this overview. The article focuses on study designs developed 
outside the mental health field to introduce concepts that might not be familiar to clinical 
researchers in mental health. Non-randomized and randomized exploratory trial design are 
covered. The article ends with a brief discussion on pilot studies and the difference to exploratory 
studies. 
Results 
Classical designs for exploratory trials such as Simon's two-stage design still have a role. 
However, randomized exploratory trials are probably more suitable for mental health 
interventions. Newer, more flexible designs such as multi-stage multi-arm trials or platform trials 
have the potential to improve the efficiency of exploratory and subsequently confirmatory 
experiments. 
Conclusions 
Although often not directly applicable, borrowing (study) design ideas from other medical 
disciplines has the potential to improve exploratory trials in the mental health field. At the same 
time, more explicit use of study designs specifically designed for exploratory trials will help to 
improve the transparency of such trials.  
  
Introduction 
Randomized-controlled trials undoubtedly provide the best evidence for causal effects of health-
care interventions e.g. their effectiveness.1 These trials are experimental studies involving human 
beings. Moreover, most health-care interventions have positive and negative effects. Before 
healthcare interventions can be tested in an experimental study a clear rationale needs to be 
provided. The rationale for an experimental study depends on the objective of the study at hand 
and the available evidence so far. For pharmaceutical products, this is represented by the 
development plan which is usually separated into four phases (I to IV).2 It should be noted that 
most health-care interventions often, but not always, develop roughly analogously over time – 
especially medical devices but also non-drug, non-device interventions. Although clinical trials 
are often labelled according to the development phase e.g. phase II trial, this approach may be 
abandoned mainly because such labels do not provide information on the objective of a particular 
trial and not necessarily match to the design. Instead, trials might be categorized according to 
their primary objective (Figure 1). 
The focus of this article is to provide an overview of study designs that precede the classical 
confirmatory randomized-controlled trial presenting classical designs and recent developments. 
As the difference between pilot studies and exploratory trials is often not unambiguous, I will 
first discuss (therapeutic) exploratory trials and then briefly describe the concept of pilot studies 
focusing on the differences between these two types of studies. It must be acknowledged that the 
current overview is neither based on a systematic literature search of methodological articles nor 
are the provided examples a representative selection. Rather, as will be shown below, approaches 
to trials that precede confirmatory trials vary across medical disciplines and the article should 
sensitize investigators to the question whether the approaches taken in other disciplines might 
also be useful in mental health. Others noted that approaches that are common or even standard in 
some medical fields are still underused in other research areas.3 The methodology for exploratory 
trials has often been developed for oncological trials and the examples provided are often but not 
always taken from there. Finally, the inefficiency of the development process of therapeutic 
interventions, especially for drugs, and the need for more efficient approaches has been discussed 
recently including also the mental health field.4 5  
Designing a therapeutic exploratory trial 
As mentioned in the introduction, the idea for therapeutic exploratory trials preceding a 
randomized-controlled trial is to provide a clear rationale for the conduct of such a trial. The 
design of such trials varies and seems to depend on the medical discipline. In disciplines such as 
cardiology or mental health, these trials are often randomized, placebo-controlled trials. In 
contrast to confirmatory trials, these trials are often limited in sample size, short-term, and 
measure surrogate outcomes with the idea that results may help to predict success in a 
confirmatory trial. For example, a recently published trial of cariprazine in patients with acute 
mania associated with bipolar I disorder measured the primary outcome (Young Mania Rating 
Scale) at three weeks.6 However, the rationale for the different design choices was rather vague 
which seems not uncommon in the mental health field according to a systematic review of trials 
in schizophrenia.7 Very few of the reviewed trials provided a clear primary hypothesis and the 
majority had no rationale for the chosen sample size. In contrast, exploratory trials in oncology 
are mainly single-arm trials that allow for interim analysis although randomized designs are more 
common nowadays given their advantages.8 In the next sections I will introduce various designs 
for exploratory trials. What is common to all these designs is that the designs provide a clear 
hypothesis and rationale for the sample size and criteria on trial success. 
The classical Simon's two stage design 
The most commonly used design and, at the same time, the origin of almost all exploratory trial 
designs is the two stage design as originally described by Simon.9 Although quite old already and 
designs with better operating characteristics exist, the design remains attractive to researchers as 
evidenced by its citation rate: according to the Web of Science and as of 2016, the original 
article9 received more than 2,000 citations overall with more than 100 citations every year since 
2004. The main reason for this is probably its simplicity and ease of implementation.  
Trials based on Simon's two-stage design consist of two parts. The design includes an early 
stopping rule after the first stage based on a test for futility i.e. the trial stops if chances to 
observe a pre-specified size of treatment effect are too small. In its original form, the design uses 
a binary outcome e.g. response to treatment and requires the researcher to specify null and 
alternative response probabilities i.e. treatment response rates that are deemed clinically 
negligible and clinically important. Conceptually, this is closely related to a non-inferiority trial.10 
It is important to realize that the determination of these probabilities is based on historical data 
and therefore the design itself implicitly is one of historical comparisons and not concomitant 
comparisons as in a randomized trial.8 In addition, Type I and II error probabilities i.e. alpha and 
power need to be fixed. The design requires to recruit the calculated number of patients of the 
first stage. If the required number of responses is not observed at the end of stage one, the trial is 
stopped early; otherwise it continues to the second stage. Success of the trial at the end of the 
second stage is determined based on whether the final observed response rate reaches the 
calculated cut-off.  
The classical design has two variants to calculate the sample sizes for the different stages and the 
cut-offs for decision-making: one that minimizes the expected sample size conditional on the null 
response probability (called optimal design) and one that minimizes the total sample size 
(minimax design) dependent on the pre-specified alpha and power. For example, assume that 
response rate of 25% is deemed clinically too low and a response rate of 50% is deemed 
clinically interesting. Then, with alpha fixed at 0.05 and power at 90% a trial will have to recruit 
16 patients in the first stage. If four or fewer patients respond, the trial is stopped early otherwise 
continues with an additional 17 patients for a total sample size of 33. If more than twelve patients 
out of these 33 responded, the trial is considered successful. The treatment is declared to be 
promising in the sense that it is likely to achieve the desirable 50% response rate. Sample size 
and cut-offs for decision-making are calculated iteratively. Routines are available in freely 
available software or websites as well as standard software packages such as Stata® 
(simontwostage and simon2stage) or R (e.g. clinfun, OneArmPhaseTwoStudy, or ph2mult).  
Variants of the classical Simon's two stage design 
Numerous variants of the classical design have been developed since the original description in 
1989 including improved algorithms to identify the best design for example: 
► Allowing for three11 12 or multiple stages13 
► Allowing to monitor two binary outcomes such as response and a safety outcome14 
► Allowing the use of continuous outcomes15 16 
► Allowing to stop early for futility and efficacy17 
The lack of a comparator arm is an important caveat of all exploratory designs. This might not be 
an issue when testing an anti-cancer agent because spontaneous improvements/responses of 
patients are unlikely. In contrast, examining the efficacy of drugs in mental health conditions 
presents a challenge in the exploratory setting as high placebo response rates are not unlikely. For 
example, a recent multi-arm trial of different doses of lurasidone in patients with acute 
schizophrenia was considered to be a "failed study" mainly because none of the experimental 
treatment arms fared better than placebo and the response rate in the placebo group was 
considered to be unusually high.18 Moreover, designs described so far all come with the price 
inherent in non-concurrent comparisons namely the difficulty to separate the inherent treatment 
effect of interest from trial effects such as patient selection, differences in co-interventions, other 
time effects, or other confounders and biases.19 Nonetheless, the idea for stopping an exploratory 
trial early for futility may be attractive as it has the potential to reduce the number of patient that 
are unnecessarily included in a trial.3 Methods for monitoring of confirmatory trials20 can be 
adapted to the exploratory setting if existing designs do not fit the individual needs. As the 
variants of the original design are (much) more complex than Simon's original proposal it is 
important to check the properties of the planned trial at the planning stage under different 
scenarios using simulation studies.  
Randomized exploratory trial designs 
To overcome the caveats, randomized exploratory designs have been proposed.21 Randomization 
in these non-confirmatory trials can serve different purposes and three main approaches have 
been identified:19 
1. Non-comparative approaches where randomized trial arms are considered separately as if 
they were single-arm trials 
2. Comparative approaches where  
a. Several experimental treatments are compared to select the most promising one for 
future trials and 
b. Experimental treatment(s) are compared to standard of care or placebo to screen 
whether an experimental treatment is actual worth for evaluating it in a definitive 
confirmatory trial 
In the first approach, several individual single-arm trials are planned using the approaches 
described above i.e. different arms may or may not have a different sample size or different 
decision rules. Although patients are eventually randomized to the different arms no comparison 
is made between arms but each arm is analyzed independently. Such a design may be useful in 
situations where the lack of a comparator arm is of minor importance (e.g. in oncology trials) but 
several experimental treatments are under consideration. Also, it is an attractive design for 
interventions early in their development phase where available clinical evidence is very limited. 
If more than one experimental treatment meets the success criterion but only one or few can be 
pursued for further evaluation still no formal comparison is done between the treatments.22 
Instead, comparisons are done informally by considering not only results on the primary outcome 
but also secondary outcomes and then the winner is picked (see second approach). However, 
formal testing frameworks in such situations have also been described.23 
The second approach (2a) is often used when several variants of an experimental intervention are 
to be evaluated e.g. different dosages, schedules etc. Patients are randomized to these different 
experimental arms and these arms are eventually ranked with the aim of selecting the most 
promising one (pick-the-winner design). Such a design was initially described by Simon, Wittes 
and Ellenberg (SWE) already in 1985.21 However, the SWE design was shown to have 
unfavorable properties especially with regard to the type I error rate.24 Therefore, it is especially 
important to run simulation studies in the planning stage to see how the trial might run under 
different scenarios.  
In the third approach (2b), patients are randomized to one or more experimental treatments and 
control with the aim to conduct non-definitive comparisons.25 in the sense that the comparison 
results could be used to motivate but not replace a confirmatory trial. Therefore, the choice of the 
parameters that determine the sample size and potentially the success of the trial is critical. This 
concerns mainly the alpha level (type I error), the power, and the effect size at which the trial is 
aiming. In particular, the alpha level will usually be higher than in a confirmatory setting. A 
recently published trial of the histamine H₃ receptor antagonist GSK239512 versus placebo for 
cognitive impairment in 80 stable schizophrenia patients might be considered as a trial that falls 
into this category.26 The rationale provided for the sample size of 80 patients was based on the 
width of the 90% confidence interval and a target effect size. Another approach to such studies 
would be to use the concept of the original Simon's two-stage design namely the non-inferiority 
framework. For example, using the information of the previously mentioned GSK239512 trial we 
can fix the following parameters: 1) target generic effect size/standardized mean difference of 
0.4, 2) non-inferiority margin at an effect size of -0.42, 3) alpha of 0.1. The power cannot be 
extracted from the article so we fix at 80%. With these parameters we arrive at a total sample size 
of 28 i.e. less than half the sample size of the original trial. Changing the assumptions to a target 
effect size of 0.3 and a non-inferiority margin of -0.3 (usually considered a small effect) we 
arrive at a sample size of 52. Obviously, these parameters need to be adjusted to the individual 
trial at hand. Moreover, an interim analysis with a test for futility could easily be implemented. 
Recently, the approaches 2a and 2b have gained new interest in the light of multi-arm multi-stage 
(MAMS) clinical trials.27 The methodology follows in principle the methodology of a standard 
randomized-controlled trial but with additional adaptive elements28 to improve the development 
process.27 Strictly speaking, such trials are not only exploratory trials but should be considered 
what is usually called seamless phase II/III trials28 and combine approach 2a and b. Patients are 
randomized among several experimental treatments and control e.g. standard of care or placebo. 
Over time, experimental treatments are dropped and in a final stage the most promising 
experimental treatment is compared to control. The selection or dropping of experimental trial 
arms over time can be achieved either by interim analyses or by adaptive randomization.29 Wason 
et al. provide a nice overview and also discusses applications for trials with continuous outcomes 
which is especially relevant for the mental health field.27  
Randomized exploratory trial designs can be fit within a frequentist or Bayesian setting. In 
general, Bayesian designs allow for more flexibility. For example, it may be easier to conduct 
more interim analyses, incorporate more outcomes in such analyses, consider correlations across 
outcomes, or add new treatment arms. This methodology is not often used as compared to 
frequentist approaches but recent advances in the methodology and related software suggest that 
Bayesian trial design might be more popular in the future. 
Platform trials 
Platform trials are typically implemented within a Bayesian framework although a frequentist 
approach is also possible. 4 30 A platform trial is an extension of a MAMS trial but usually with 
broader goals and a much more flexible trial protocol. The main aim is to find the best treatment 
option(s). The main difference to the trials discussed so far is that a platform trial runs long-term 
i.e. potentially for an indefinite amount of time or as long as there are suitable treatments under 
evaluation because trial arms are dropped and added continously.4 Decision-rules guide the 
process of adding or dropping treatment arms, changes in eligibility criteria e.g. dropping patient 
subgroups, or combining treatments in a new arm. To the best of my knowledge, only one trial, in 
breast cancer patients, has published first results using such a design.31 32 However, others are 
underway including a trial in Alzheimer's disease.33 
A primer on pilot studies 
Pilot studies have long been neglected in clinical research. However, such studies have recently 
gained attention as evidenced by a recently published extension to the CONSORT statement34 or 
the emergence of peer-reviewed journal dedicated to the publication for such studies 
(https://pilotfeasibilitystudies.biomedcentral.com/). A conceptual framework to distinguish pilot 
studies from other types of studies is also now available.35 Within this framework, pilot studies 
evaluate parts or the complete planned confirmatory trial. The idea of these studies is not to test 
whether a treatment is promising for confirmatory testing in a randomized-controlled trial as it is 
in a (therapeutic) exploratory trial. Rather, such studies evaluate the feasibility of the study 
design and directly precede a confirmatory trial – if successful.36 Common domains to be 
evaluated in a pilot study are:  
► Recruitment potential 
► Recruitment, informed consent, or randomization process 
► Assessments and outcome measures 
► Data collection and follow-up 
► Resource use and costs 
► Collecting outcome data to inform the sample size calculation of the main trial 
As such, these studies can be quantitative as well as qualitative and may be conducted separately 
from the main trial or nested within the main trial (internal pilot). Although some internal 
piloting is common to most randomized-controlled trials37 it should be stressed that these are 
usually not formally defined but conducted rather informally. In contrast, a true pilot study has a 
study protocol and pre-specified outcomes although some flexibility is inevitable and actually 
desirable.38 Retrospective analyses of trials that were discontinued prematurely suggest that 
performing a full pilot study before the actual trial is protective against premature discontinuation 
especially with regard to poor recruitment.39 Their usefulness is therefore generally not 
challenged. Thus, whether to conduct a pilot or not is mainly determined by available time and 
resources. 
Conclusions 
Over the last ten to 20 years a rich body of methodological work has been published on study 
designs for therapeutic exploratory trials. Designs for almost all situations are available. It is 
therefore surprising that the quality of such trials is still poor including unspecified hypothesis, 
unclear objectives, and non-existing sample size justifications.7 One reason maybe that 
investigators feel uncomfortable in borrowing ideas from other medical disciplines or feel that 
these approaches are not applicable to their situation. However, from my experience similarities 
usually outweigh the differences. Moreover, most designs are flexible and can be adapted to fit 
the individual needs. It is therefore hoped that we will see more efficient development of health-
care interventions in the near future with more transparent and at the same time comprehensive 
and flexible trials. 
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Figure 1: Development process of health-care interventions (drugs) and related trials 
 
 
